{"DataElement":{"publicId":"6180734","version":"1","preferredName":"Oropharyngeal p16-Negative Cancer AJCC Edition 8 Clinical Regional Lymph Node N Category","preferredDefinition":"Extent of the regional lymph node involvement for p16-negative oropharyngeal carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed. criteria.","longName":"OX16N_AJC8_CLN_N_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6052653","version":"1","preferredName":"Oropharynx Neoplasm CDKN2A-p16 Negative Clinical N Category","preferredDefinition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Indicates that expression of the p16 form of CDKN2A has not been detected in a sample._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","longName":"6052651v1.0:6072196v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6052651","version":"1","preferredName":"Oropharynx Neoplasm","preferredDefinition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12762:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharynx","conceptCode":"C12762","definition":"The part of the pharynx between the soft palate and the upper portion of the epiglottis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630C1054-6248-5BD4-E053-F662850A4B08","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6072196","version":"1","preferredName":"CDKN2A-p16 Negative Clinical N Stage","preferredDefinition":"Indicates that expression of the p16 form of CDKN2A has not been detected in a sample.:Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:One criteria of the TNM staging system.  N refers to the extent of lymph node involvement.","longName":"C132226:C25398:C25580","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDKN2A-p16 Negative","conceptCode":"C132226","definition":"Indicates that expression of the p16 form of CDKN2A has not been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6541BD54-519A-7A45-E053-F662850A9C45","latestVersionIndicator":"Yes","beginDate":"2018-02-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-02-15","modifiedBy":"ONEDATA","dateModified":"2018-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"630C1054-626A-5BD4-E053-F662850A4B08","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt released. 1/18/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6052686","version":"1","preferredName":"Oropharyngeal (p16-Negative) Carcinoma American Joint Committee on Cancer Edition 8 Clinical N Category","preferredDefinition":"A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system.  N refers to the extent of lymph node involvement._A grouping of items based on some commonality or by user defined characteristics.","longName":"6052686v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"NX","valueDescription":"Oropharyngeal (p16-Negative) Cancer cNX TNM Finding v8","ValueMeaning":{"publicId":"6052688","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cNX TNM Finding v8","longName":"6052688","preferredDefinition":"Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cNX TNM Finding v8","conceptCode":"C132939","definition":"Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7D1C-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7D35-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N3b","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN3b TNM Finding v8","ValueMeaning":{"publicId":"6052690","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN3b TNM Finding v8","longName":"6052690","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN3b TNM Finding v8","conceptCode":"C132957","definition":"Oropharyngeal (p16-negative) cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7D42-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7D5B-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N3a","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN3a TNM Finding v8","ValueMeaning":{"publicId":"6052692","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN3a TNM Finding v8","longName":"6052692","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN3a TNM Finding v8","conceptCode":"C132955","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7D68-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7D81-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N3","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN3 TNM Finding v8","ValueMeaning":{"publicId":"6052694","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN3 TNM Finding v8","longName":"6052694","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN3 TNM Finding v8","conceptCode":"C132953","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7D8E-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7DA7-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2c","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN2c TNM Finding v8","ValueMeaning":{"publicId":"6052696","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN2c TNM Finding v8","longName":"6052696","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN2c TNM Finding v8","conceptCode":"C132951","definition":"Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7DB4-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7DCD-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2b","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN2b TNM Finding v8","ValueMeaning":{"publicId":"6052698","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN2b TNM Finding v8","longName":"6052698","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN2b TNM Finding v8","conceptCode":"C132949","definition":"Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7DDA-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7DF3-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2a","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN2a TNM Finding v8","ValueMeaning":{"publicId":"6052700","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN2a TNM Finding v8","longName":"6052700","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN2a TNM Finding v8","conceptCode":"C132947","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7E00-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7E19-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N2","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN2 TNM Finding v8","ValueMeaning":{"publicId":"6052702","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN2 TNM Finding v8","longName":"6052702","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN2 TNM Finding v8","conceptCode":"C132945","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7E26-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7E3F-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N1","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN1 TNM Finding v8","ValueMeaning":{"publicId":"6052704","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN1 TNM Finding v8","longName":"6052704","preferredDefinition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN1 TNM Finding v8","conceptCode":"C132943","definition":"Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7E4C-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7E65-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"},{"value":"N0","valueDescription":"Oropharyngeal (p16-Negative) Cancer cN0 TNM Finding v8","ValueMeaning":{"publicId":"6052706","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer cN0 TNM Finding v8","longName":"6052706","preferredDefinition":"Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer cN0 TNM Finding v8","conceptCode":"C132941","definition":"Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7E72-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"630DB71D-7E8B-0231-E053-F662850A8DE6","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6052685","version":"1","preferredName":"Oropharyngeal (p16-Negative) Cancer Clinical Regional Lymph Nodes TNM Finding v8 American Joint Committee on Cancer N Category Category","preferredDefinition":"A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system.  N refers to the extent of lymph node involvement.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C132935:C39315:C25580:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal (p16-Negative) Cancer Clinical Regional Lymph Nodes TNM Finding v8","conceptCode":"C132935","definition":"A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"630DB71D-7CEF-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"ONEDATA","dateModified":"2018-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"630DB71D-7D00-0231-E053-F662850A8DE6","latestVersionIndicator":"Yes","beginDate":"2018-01-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-18","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt released. 1/18/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6052641","version":"1","longName":"Oropharyngeal","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Clinical N category","type":"Preferred Question Text","description":"Clinical N category","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"696B1A80-A0AB-3582-E053-F662850ABE32","latestVersionIndicator":"Yes","beginDate":"2018-04-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-04-09","modifiedBy":"TAYLORT","dateModified":"2018-04-09","changeDescription":"4/9/18 tt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}